Ruth Witt

发表

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

S. Pfister, T. Hielscher, O. Witt, 2012, Clinical Epigenetics.

Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

David T. W. Jones, F. Westermann, B. Burkhardt, 2016, European journal of cancer.

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

S. Pfister, T. Hielscher, O. Witt, 2019, Clinical Epigenetics.

Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.

David T. W. Jones, P. Lichter, S. Pfister, 2019, European journal of cancer.

The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

David C. Jones, F. Westermann, B. Burkhardt, 2021, Cancer discovery.

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

David T. W. Jones, C. Plass, I. Harting, 2020, BMC Cancer.

CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION

David C. Jones, O. Witt, D. Hargrave, 2022, Neuro-Oncology.

Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors

David T. W. Jones, S. Pfister, T. Hielscher, 2016, Brain pathology.

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

S. Pfister, T. Hielscher, O. Witt, 2019, Clinical Epigenetics.

Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.

David C. Jones, N. Jäger, S. Pfister, 2023, JCO precision oncology.

Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach

Annette Kopp-Schneider, Manuel Wiesenfarth, Ulrich Abel, 2018, Biometrical journal. Biometrische Zeitschrift.

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

D. Capper, F. Sahm, T. Milde, 2024, BMC cancer.